VEGFA and neoplasm: Bevacizumab, a vascular endothelial growth factor (VEGF)-A targeting monoclonal antibody, can only prolong progression-free survival in recurrent GBM, while combination therapy, although it reduces the aggressiveness of the tumor in the initial phase, does not significantly affect the course of the disease [8,9,10].